About The Study: Hospitals and health systems administered more than 158,000 anti–SARS-CoV-2 monoclonal antibodies (mAbs) doses in early 2022 despite Food and Drug Administration (FDA) deauthorization because of a lack of efficacy against the Omicron variant. Medicare payments for mAb administration range from $450 to $750 per dose, indicating that spending on these deauthorized treatments likely exceeds $71 million. The findings suggest that the use of deauthorized mAb products was widespread, even though patients had a minimal likelihood of benefit.
Authors: Timothy S. Anderson, M.D., M.A.S., of Beth Israel Deaconess Medical Center in Boston, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2022.28997)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.28997?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=082922
JAMA Network Open